Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer

被引：5

作者：

McNamara, Blair ^{[1
]}

Chang, Yifan ^{[1
]}

Mutlu, Levent ^{[1
]}

Harold, Justin ^{[1
]}

Santin, Alessandro D. ^{[1
]}

机构：

[1] Yale Univ, Dept Obstet Gynecol & Reprod Sci, Sch Med, 333 Cedar St,LSOG 305,POB 208063, New Haven, CT 06520 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2023年 / 23卷 / 03期

关键词：

Cervical cancer; immune checkpoint inhibitor; PD-1; pembrolizumab; bevacizumab; HUMAN-PAPILLOMAVIRUS; MONOCLONAL-ANTIBODY; INTRAEPITHELIAL NEOPLASIA; EXPRESSION; EFFICACY; SAFETY; WOMEN; ANGIOGENESIS; STIMULATION; STATISTICS;

D O I：

10.1080/14712598.2023.2182679

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

IntroductionDespite progress on prevention and treatment of cervical cancer, global morbidity and mortality remain high. Immunotherapy, in conjunction with standard chemotherapy, presents an opportunity for further benefit.Areas coveredHere we report the pharmacologic properties, evidence for clinical efficacy, safety, and tolerability of pembrolizumab in addition to standard chemotherapy with and without bevacizumab for treatment of advanced or recurrent cervical cancer.Expert opinionIn patients with progressive, recurrent, or metastatic PD-L1 expressing cervical cancer, without contraindication to anti-VEGF therapy, the use of pembrolizumab with bevacizumab and standard chemotherapy with carboplatin and paclitaxel is warranted. There is no evidence to support the use of pembrolizumab for this population broadly, and no evidence to support its use in PD-L1 non-expressing tumors.

引用

页码：227 / 233

页数：7

共 58 条

[1] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States [J].

Aguiar-Ibanez, Raquel ;

Hardern, Chloe ;

van Hees, Frank ;

Lee, Dawn ;

Patel, Anubhav ;

Chhabra, Nitika ;

Baluni, Gargi ;

Amonkar, Mayur ;

Lai, Yizhen ;

Xu, Ruifeng ;

Massaad, Rachid ;

Fogelman, David .

JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) :469-480

[2] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation [J].

Allen, Elizabeth ;

Jabouille, Arnaud ;

Rivera, Lee B. ;

Lodewijckx, Inge ;

Missiaen, Rindert ;

Steri, Veronica ;

Feyen, Kevin ;

Tawney, Jaime ;

Hanahan, Douglas ;

Michael, Iacovos P. ;

Bergers, Gabriele .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)

[3]

[Anonymous], CANC CERV UT CANC ST

[4] Cancer of the cervix uteri [J].

Bhatla, Neerja ;

Aoki, Daisuke ;

Sharma, Daya Nand ;

Sankaranarayanan, Rengaswamy .

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :22-36

[5] Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer [J].

Borcoman, Edith ;

Le Tourneau, Christophe .

ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)

[6] An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors [J].

Breij, Esther C. W. ;

de Goeij, Bart E. C. G. ;

Verploegen, Sandra ;

Schuurhuis, Danita H. ;

Amirkhosravi, Ali ;

Francis, John ;

Miller, Vibeke Breinholt ;

Houtkamp, Mischa ;

Bleeker, Wim K. ;

Satijn, David ;

Parren, Paul W. H. I. .

CANCER RESEARCH, 2014, 74 (04) :1214-1226

[7] A THEORY OF SELF-NONSELF DISCRIMINATION [J].

BRETSCHER, P ;

COHN, M .

SCIENCE, 1970, 169 (3950) :1042-+

[8] Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries [J].

Brisson, Marc ;

Kim, Jane J. ;

Canfell, Karen ;

Drolet, Melanie ;

Gingras, Guillaume ;

Burger, Emily A. ;

Martin, Dave ;

Simms, Kate T. ;

Benard, Elodie ;

Boily, Marie-Claude ;

Sy, Stephen ;

Regan, Catherine ;

Keane, Adam ;

Caruana, Michael ;

Nguyen, Diep T. N. ;

Smith, Megan A. ;

Laprise, Jean-Francois ;

Jit, Mark ;

Alary, Michel ;

Bray, Freddie ;

Fidarova, Elena ;

Elsheikh, Fayad ;

Bloem, Paul J. N. ;

Broutet, Nathalie ;

Hutubessy, Raymond .

LANCET, 2020, 395 (10224) :575-590

[9] Integrated genomic and molecular characterization of cervical cancer [J].

Burk, Robert D. ;

Chen, Zigui ;

Saller, Charles ;

Tarvin, Katherine ;

Carvalho, Andre L. ;

Scapulatempo-Neto, Cristovam ;

Silveira, Henrique C. ;

Fregnani, Jose H. ;

Creighton, Chad J. ;

Anderson, Matthew L. ;

Castro, Patricia ;

Wang, Sophia S. ;

Yau, Christina ;

Benz, Christopher ;

Robertson, A. Gordon ;

Mungall, Karen ;

Lim, Lynette ;

Bowlby, Reanne ;

Sadeghi, Sara ;

Brooks, Denise ;

Sipahimalani, Payal ;

Mar, Richard ;

Ally, Adrian ;

Clarke, Amanda ;

Mungall, Andrew J. ;

Tam, Angela ;

Lee, Darlene ;

Chuah, Eric ;

Schein, Jacqueline E. ;

Tse, Kane ;

Kasaian, Katayoon ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Balasundaram, Miruna ;

Thiessen, Nina ;

Dhalla, Noreen ;

Carlsen, Rebecca ;

Moore, Richard A. ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Wong, Tina ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Kucherlapati, Raju ;

Hadjipanayis, Angela ;

Seidman, Jonathan ;

Kucherlapati, Melanie ;

Ren, Xiaojia ;

Xu, Andrew W. .

NATURE, 2017, 543 (7645) :378-+

[10] SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation [J].

Chemnitz, JM ;

Parry, RV ;

Nichols, KE ;

June, CH ;

Riley, JL .

JOURNAL OF IMMUNOLOGY, 2004, 173 (02) :945-954

← 1 2 3 4 5 6 →